Nodular Lymphocyte-Predominant Hodgkin Lymphoma
An indolent, biologically distinct form of Hodgkin lymphoma defined by characteristic 'popcorn' lymphocyte-predominant cells, generally associated with favorable long-term outcomes.
- Generally Indolent Course
- High Cure Potential with Specialist Care
- Tailored, Less Intensive Treatment Options
- Long-Term Survivorship Support
- Disease Type
- Indolent Hodgkin Lymphoma Subtype
- Key Cell Type
- LP ('Popcorn') Cells
- Most Common In
- Young to Middle-Aged Adults, Male Predominance
- Advanced Therapies
- Rituximab, Tailored Regimens
Condition Overview
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma that behaves quite differently from classical Hodgkin lymphoma. It is defined by the presence of characteristic lymphocyte-predominant (LP) cells, sometimes called 'popcorn cells' for their distinctive appearance, set within a background rich in normal lymphocytes.
NLPHL most commonly affects younger to middle-aged adults, with a notable predominance in men, and typically presents as localized lymph node enlargement, often in the neck or underarm region. Compared with classical Hodgkin lymphoma, NLPHL generally follows a more indolent course, and many patients are diagnosed at an early stage with disease confined to one or a few lymph node regions.
Because of its generally favorable biology, treatment approaches for NLPHL are often less intensive than those used for classical Hodgkin lymphoma, though careful specialist evaluation is important to confirm the diagnosis and tailor treatment, since the disease can occasionally transform into a more aggressive B-cell lymphoma.
Types and Presentations
NLPHL is generally described by its extent of disease and pattern at diagnosis rather than by distinct molecular subtypes.
Symptoms and Signs
NLPHL most often presents with painless lymph node enlargement, and systemic symptoms are less common than in classical Hodgkin lymphoma.
Causes and Risk Factors
The exact cause of NLPHL is unknown, and unlike classical Hodgkin lymphoma, it is not strongly associated with Epstein-Barr virus infection.
Diagnosis and Investigations
Diagnosing NLPHL requires lymph node biopsy with careful pathology review to identify the characteristic LP cells and distinguish it from classical Hodgkin lymphoma and other B-cell lymphomas.
Disease Staging and Risk Stratification
NLPHL is staged using the Ann Arbor/Lugano system applied to Hodgkin lymphoma, with most patients presenting at an early stage.
Standard Treatment Options
Because NLPHL generally behaves less aggressively than classical Hodgkin lymphoma, treatment is often tailored to be less intensive, particularly for early-stage disease.
Advanced and Emerging Treatment Options
Because LP cells express B-cell markers, NLPHL responds to several B-cell-directed therapies not typically used in classical Hodgkin lymphoma.
Immunotherapy
Anti-CD20 Monoclonal Antibody (Rituximab)
Used alone or with chemotherapy given the CD20 expression on LP cells, reflecting the B-cell biology of NLPHL.
Transplant
Autologous Stem Cell Transplant
Considered for relapsed or refractory disease in eligible patients.
Targeted
Novel B-Cell-Directed Agents
Therapies developed for other CD20-positive B-cell lymphomas are being explored for relapsed NLPHL in select cases.
Cellular Therapy
CAR-T Cell Therapy
Considered in clinical trials for select cases of relapsed disease, particularly where transformation to an aggressive B-cell lymphoma has occurred.
Biomarkers and Precision Medicine
Immunophenotypic confirmation of LP cells is central to diagnosing NLPHL and distinguishing it from classical Hodgkin lymphoma.
When a Second Opinion May Be Important
Because treatment approaches for NLPHL differ meaningfully from classical Hodgkin lymphoma, a specialist second opinion can help ensure the most appropriate, least intensive effective approach is chosen.
Clinical Trials and Research
Prognosis and Key Outcome Factors
NLPHL is generally associated with excellent long-term outcomes, particularly for early-stage disease, though ongoing surveillance is recommended given the possibility of late relapse or transformation.
Supportive Care and Living With NLPHL
Supportive care for NLPHL focuses on managing treatment effects and supporting long-term survivorship, given the often younger age at diagnosis.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with NLPHL access specialist pathology confirmation, coordinate second opinions, and explore tailored, less intensive treatment options through our specialist network.
Get a free case reviewFrequently Asked Questions
NLPHL is a distinct, generally indolent subtype of Hodgkin lymphoma defined by characteristic 'popcorn' lymphocyte-predominant cells, which biologically behave differently from classical Hodgkin lymphoma.
The most common first sign is painless, slowly enlarging lymph node swelling, often in the neck or underarm region.
No. While both are grouped under Hodgkin lymphoma, NLPHL has a distinct cell of origin, immunophenotype, and generally more indolent clinical behavior.
Many patients, especially those with early-stage disease, achieve long-term remission, and outcomes are generally excellent with appropriate treatment.
Early-stage disease is often treated with localized radiation alone, while more advanced disease may require chemotherapy combined with anti-CD20 antibody therapy.
Relapse can occur, sometimes years after initial treatment, which is why long-term surveillance is recommended.
In a small proportion of cases, NLPHL can transform into an aggressive large B-cell lymphoma, which requires prompt re-biopsy and more intensive treatment.
Diagnosis requires a lymph node biopsy with detailed immunophenotyping to confirm the characteristic LP-cell pattern and CD20 expression.
Stage at diagnosis, histologic growth pattern, and response to initial treatment are key factors that influence long-term outcomes.
Yes. CancerFax can help you submit your pathology reports for specialist review, arrange a second opinion, and explore tailored treatment options, including access to advanced therapies and survivorship support.
Get Expert Guidance for NLPHL
Connect with lymphoma specialists to confirm your diagnosis and discuss the most appropriate, least intensive treatment approach.